Presiding over the upward trajectory of Eli Lilly over the last eight years is paying off nicely for CEO David Ricks. | ...

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Eli Lilly. Looking at options history for Eli ...

Financial giants have made a conspicuous bullish move on Eli Lilly. Our analysis of options history for Eli Lilly (NYSE:LLY) revealed 17 unusual trades. Delving into the details, we found 52% of ...

Eli Lilly’s profit doubled in the fourth quarter ... Revenue from the breast cancer treatment Verzenio also helped in the fourth quarter, climbing 36% to $1.55 billion. Overall, Lilly’s ...